The Galectin 3 Inhibitor Market is emerging as a promising therapeutic segment driven by expanding fibrosis and chronic disease research, rising investment in novel therapeutics, and a growing clinical pipeline for galectin-3 targeted treatments. The market was estimated at approximately USD 0.75 billion in 2025 and is projected to grow at a CAGR of 12–20% through 2033, potentially...
Bangla